Form 4: Alector R&D Head Sells Shares for Tax Obligations

Alector's President and Head of R&D, Sara Kenkare-Mitra, sold 41,687 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Sara Kenkare-Mitra, President and Head of R&D at Alector, Inc., reported a transaction involving the company's common stock.
• On December 3, 2025, Kenkare-Mitra disposed of 41,687 shares of Alector common stock.
• The shares were sold at a weighted average price of $1.1196 per share, with individual transactions ranging from $1.095 to $1.14.
• The purpose of the sale was to satisfy tax obligations incurred due to the vesting of restricted stock units (RSUs).
• Following this transaction, Kenkare-Mitra beneficially owns 501,652 shares of Alector common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-arranged sale.

Sentiment

Score: 5

Explanation: The transaction is a routine, tax-related insider sale, which is generally considered a neutral event and does not reflect positively or negatively on the company's operational performance or future outlook.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider's stock transaction.

Management Comments

• The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.

Industry Context

Insider transactions, particularly sales to cover tax obligations upon RSU vesting, are common occurrences across all industries, including the biotechnology sector where Alector operates. These types of transactions are often pre-scheduled under Rule 10b5-1 plans and are generally considered routine compensation-related events rather than indicators of management's sentiment about the company's future prospects.

Comparison to Industry Standards

• The transaction is a standard insider sale for tax purposes, a common practice among executives in publicly traded companies, particularly in sectors like biotech where RSU compensation is prevalent.
• The use of a Rule 10b5-1 plan aligns with best practices for insiders to avoid accusations of trading on material non-public information, a standard adopted by many executives across various industries.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned transaction for tax purposes and not indicative of a change in fundamental company value or management's confidence.
• Employees: The vesting of RSUs is a standard component of executive compensation, reinforcing the company's compensation structure.

Key Dates

Recommendation

The reported transaction is a routine insider sale to cover tax obligations associated with the vesting of restricted stock units, often pre-arranged under a Rule 10b5-1 plan. Such transactions are generally not indicative of management's view on the company's future prospects and do not typically warrant a change in investment recommendation based solely on this filing. Investors should focus on Alector's operational performance, clinical pipeline, and financial results for investment decisions.

Keywords

Alector, ALEC, Form 4, insider transaction, stock sale, RSU vesting, tax obligations, Kenkare-Mitra Sara, common stock, Rule 10b5-1